Executive Director, Clinical Operations

Melissa Holmes is Executive Director, Clinical Operations at Avenzo Therapeutics. She has over 20 years of experience in Phase 1 through Phase 4 clinical trials and has deep expertise in oncology clinical development.

Ms. Holmes most recently served as the Executive Director, Clinical Operations at Adcentrx Therapeutics. Prior to joining Adcentrx, she was the Senior Director, Clinical Operations at Turning Point Therapeutics, which was acquired by Bristol Myers Squibb in 2022. She has also held similar positions in clinical operations at Ambit Biosciences, Ardea Biosciences, Arena Pharmaceuticals (subsequently acquired by Pfizer), Neurocrine Biosciences, and Cato Research (now Allucent).

Ms. Holmes holds a B.S. in Biology from Elon University in North Carolina.